Astrazeneca (AZN) FCF Margin (2009 - 2026)

Astrazeneca (AZN) has reported FCF Margin for 17 consecutive years, with 710.39% the latest figure, recorded in Q1 2026.

• In Q1 2026, FCF Margin rose 13066.0% year-over-year to 710.39%; the TTM figure through Mar 2026 stood at 2639.22% (down 243838.0% YoY), while the FY2025 annual figure was 27.11%, down 148968.0% from the prior year.
• FCF Margin came in at 710.39% for Q1 2026 at Astrazeneca, up from 76400.0% in the prior quarter.
• The five-year high for FCF Margin was 9550.0% in Q2 2024, with the low at 76400.0% in Q4 2025.
• Average FCF Margin over 5 years is 3097.3%, with a median of 710.39% recorded in 2026.
• Across the five-year window, FCF Margin jumped 941010 bps in 2024 and slumped 7601472 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 8433.33% in 2022, then tumbled by 98 bps to 139.9% in 2023, then plunged by 375 bps to 385.28% in 2024, then plunged by 19730 bps to 76400.0% in 2025, then jumped by 101 bps to 710.39% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 710.39%, 76400.0%, and 6236.36% for Q1 2026, Q4 2025, and Q3 2025 respectively.